AVL-292 is primarily used in biomedical research as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). This makes it valuable in studying B-cell receptor signaling pathways, which play a critical role in the development and function of B cells. Due to its ability to block BTK activity, AVL-292 is investigated for its potential in treating B-cell malignancies and autoimmune diseases such as chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma, and rheumatoid arthritis. Its high selectivity reduces off-target effects, making it a useful tool compound in preclinical studies aimed at understanding the therapeutic impact of BTK inhibition. AVL-292 is not used clinically but serves as an important reference in the development of BTK-targeted therapies.